CN102458419A - 组合物用于治疗粘膜炎的用途 - Google Patents
组合物用于治疗粘膜炎的用途 Download PDFInfo
- Publication number
- CN102458419A CN102458419A CN2010800254173A CN201080025417A CN102458419A CN 102458419 A CN102458419 A CN 102458419A CN 2010800254173 A CN2010800254173 A CN 2010800254173A CN 201080025417 A CN201080025417 A CN 201080025417A CN 102458419 A CN102458419 A CN 102458419A
- Authority
- CN
- China
- Prior art keywords
- compositions
- chitosan
- scope
- mucositis
- electronegative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 131
- 238000011282 treatment Methods 0.000 title claims abstract description 42
- 206010028116 Mucosal inflammation Diseases 0.000 title claims abstract description 34
- 201000010927 Mucositis Diseases 0.000 title claims abstract description 33
- 229920001661 Chitosan Polymers 0.000 claims abstract description 63
- 150000004676 glycans Chemical class 0.000 claims abstract description 49
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 49
- 239000005017 polysaccharide Substances 0.000 claims abstract description 49
- 229920000669 heparin Polymers 0.000 claims abstract description 32
- 229960002897 heparin Drugs 0.000 claims abstract description 30
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 10
- 229960000633 dextran sulfate Drugs 0.000 claims abstract description 10
- 230000000699 topical effect Effects 0.000 claims abstract description 5
- 208000003265 stomatitis Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000002512 chemotherapy Methods 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 150000002500 ions Chemical class 0.000 claims description 13
- 238000001959 radiotherapy Methods 0.000 claims description 12
- 238000003381 deacetylation reaction Methods 0.000 claims description 10
- 238000009168 stem cell therapy Methods 0.000 claims description 10
- 238000009580 stem-cell therapy Methods 0.000 claims description 10
- 230000006196 deacetylation Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000013530 defoamer Substances 0.000 claims description 6
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 208000018925 gastrointestinal mucositis Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 210000000214 mouth Anatomy 0.000 description 15
- 208000025865 Ulcer Diseases 0.000 description 13
- 231100000397 ulcer Toxicity 0.000 description 13
- 230000036407 pain Effects 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 206010040943 Skin Ulcer Diseases 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 231100000019 skin ulcer Toxicity 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 4
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000010813 municipal solid waste Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011814 protection agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 241000238040 Panulirus Species 0.000 description 1
- 241000927735 Penaeus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000010393 epithelial cell migration Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0950441-6 | 2009-06-10 | ||
| SE0950441 | 2009-06-10 | ||
| PCT/SE2010/050650 WO2010144044A1 (en) | 2009-06-10 | 2010-06-10 | Use of a composition for the treatment of mucositis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102458419A true CN102458419A (zh) | 2012-05-16 |
Family
ID=43309105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800254173A Pending CN102458419A (zh) | 2009-06-10 | 2010-06-10 | 组合物用于治疗粘膜炎的用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8906883B2 (enExample) |
| EP (1) | EP2440216A4 (enExample) |
| JP (1) | JP2012529506A (enExample) |
| CN (1) | CN102458419A (enExample) |
| AU (1) | AU2010259284A1 (enExample) |
| BR (1) | BRPI1009741A2 (enExample) |
| CA (1) | CA2763092A1 (enExample) |
| RU (1) | RU2011152518A (enExample) |
| WO (1) | WO2010144044A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164430A (zh) * | 2018-06-03 | 2021-07-23 | 格莱科米拉治疗公司 | 用于在暴露于电离辐射和/或化学疗法之后预防严重健康后果和/或组织损伤的方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2773017T3 (es) | 2010-04-06 | 2020-07-09 | Synedgen Inc | Derivados de quitosano para el tratamiento de mucositis o ulceración |
| US10022393B2 (en) | 2012-09-20 | 2018-07-17 | Synedgen, Inc. | Methods for treatment or prevention of damage resulting from radiation, trauma or shock |
| CN105451745B (zh) * | 2013-08-13 | 2018-03-27 | 生化学工业株式会社 | 含有阳离子化壳聚糖的药物 |
| JP2016534057A (ja) * | 2013-10-22 | 2016-11-04 | カンテックス ファーマシューティカルズ， インコーポレイテッド | 放射線傷害を処置および予防する方法 |
| JP6315741B2 (ja) * | 2015-08-18 | 2018-04-25 | 合同会社Ｐｈａｒｍａ Ｓｅｅｄｓ Ｃｒｅａｔｅ | ＮＳＡＩＤｓまたはヘパリン類含有口腔用組成物 |
| WO2019211483A1 (en) * | 2018-05-04 | 2019-11-07 | Bonoss Medical Aktiebolag | A composition for reduction of scar formation |
| WO2021216494A1 (en) * | 2020-04-24 | 2021-10-28 | Intact Therapeutics, Inc. | Compositions and methods for treatment of gastrointestinal bleeding |
| EP3981505B1 (en) * | 2020-10-12 | 2024-11-27 | Gambro Lundia AB | Membrane with immobilized anticoagulant and process for producing same |
| EP4401784A4 (en) * | 2021-09-17 | 2025-09-10 | Shawn Walker | USE OF CHITOSAN COMPLEXES OR COMPOSITIONS TO REDUCE THE INFILTRATION OF ENVIRONMENTAL FACTORS INTO THE BRAIN |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227493A (zh) * | 1996-08-06 | 1999-09-01 | 梅迪卡布公司 | 肝素或硫酸乙酰肝素与脱乙酰壳多糖结合用于预防或治疗由疱疹病毒引起的感染 |
| CN1627948A (zh) * | 2002-04-24 | 2005-06-15 | 麦迪卡博公司 | 治疗炎症性肠病的组合物和试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9402531L (sv) * | 1994-07-19 | 1996-01-20 | Medicarb Ab | Sårläkningsmedel |
| SE9402529D0 (sv) * | 1994-07-19 | 1994-07-19 | Astra Ab | Anti-adherensmedel |
| EP1363600B1 (en) * | 2001-02-15 | 2008-10-01 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| EP1383521A2 (en) * | 2001-04-23 | 2004-01-28 | Nucryst Pharmaceuticals Corp. | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| US20040167099A1 (en) * | 2002-10-07 | 2004-08-26 | Orapharma, Inc. | Mucoadhesive tetracycline formulations |
| JP2008513455A (ja) * | 2004-09-14 | 2008-05-01 | モレキュラー セラピューティクス インコーポレーティッド | 改良された生物薬剤学的性質をもつｄ−メチオニン製剤 |
| JP2008527033A (ja) * | 2005-01-19 | 2008-07-24 | ボンオス・メディカル・アー・ベー | 増殖因子組成物 |
| DE102006024831B4 (de) * | 2006-05-24 | 2008-03-27 | Heraeus Quarzglas Gmbh & Co. Kg | Verfahren zur Herstellung eines Halbzeugs aus synthetischem Quarzglas |
| US20080299050A1 (en) | 2006-10-05 | 2008-12-04 | Drugtech Corporation | Topical therapies for oral mucositis and other conditions |
-
2010
- 2010-06-10 RU RU2011152518/15A patent/RU2011152518A/ru not_active Application Discontinuation
- 2010-06-10 US US13/376,947 patent/US8906883B2/en not_active Expired - Fee Related
- 2010-06-10 CN CN2010800254173A patent/CN102458419A/zh active Pending
- 2010-06-10 AU AU2010259284A patent/AU2010259284A1/en not_active Abandoned
- 2010-06-10 JP JP2012514923A patent/JP2012529506A/ja active Pending
- 2010-06-10 EP EP10786461.3A patent/EP2440216A4/en not_active Withdrawn
- 2010-06-10 BR BRPI1009741A patent/BRPI1009741A2/pt not_active IP Right Cessation
- 2010-06-10 WO PCT/SE2010/050650 patent/WO2010144044A1/en not_active Ceased
- 2010-06-10 CA CA2763092A patent/CA2763092A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227493A (zh) * | 1996-08-06 | 1999-09-01 | 梅迪卡布公司 | 肝素或硫酸乙酰肝素与脱乙酰壳多糖结合用于预防或治疗由疱疹病毒引起的感染 |
| CN1627948A (zh) * | 2002-04-24 | 2005-06-15 | 麦迪卡博公司 | 治疗炎症性肠病的组合物和试剂盒 |
Non-Patent Citations (1)
| Title |
|---|
| 托马斯: "《临床实验诊断学-实验结果的应用和评估》", 31 May 2004, 上海科学技术出版社, article "单纯疱疹病毒（HSV）1型", pages: 1236 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164430A (zh) * | 2018-06-03 | 2021-07-23 | 格莱科米拉治疗公司 | 用于在暴露于电离辐射和/或化学疗法之后预防严重健康后果和/或组织损伤的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2763092A1 (en) | 2010-12-16 |
| BRPI1009741A2 (pt) | 2016-03-15 |
| JP2012529506A (ja) | 2012-11-22 |
| AU2010259284A1 (en) | 2011-12-15 |
| WO2010144044A1 (en) | 2010-12-16 |
| RU2011152518A (ru) | 2013-07-20 |
| EP2440216A4 (en) | 2013-09-11 |
| US20120077773A1 (en) | 2012-03-29 |
| US8906883B2 (en) | 2014-12-09 |
| EP2440216A1 (en) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102458419A (zh) | 组合物用于治疗粘膜炎的用途 | |
| JP4354528B2 (ja) | 間質性膀胱炎の治療へのヒアルロン酸の使用 | |
| AU753124B2 (en) | Dextran formulations and method for treatment of inflammatory joint disorders | |
| US6828308B2 (en) | Compositions and methods for the treatment or prevention of inflammation | |
| US20020173485A1 (en) | Compositions and methods for the treatment or prevention of inflammation | |
| EP2034956B2 (en) | Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis | |
| JP2002511057A (ja) | 局所薬剤製剤 | |
| ES2688971T3 (es) | Uso de oligouronatos | |
| KR20040089628A (ko) | 생체내에서 상전이하는 액상 매트릭스 및 액상 경구 제제 | |
| JPH02237929A (ja) | 胃腸粘膜組織障害疾患治療剤 | |
| US11826380B2 (en) | Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments | |
| ES2219070T3 (es) | Uso de acido haluronico en el tratamiento de la cistitis por radiacion. | |
| JP6595717B2 (ja) | 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法 | |
| US7141251B2 (en) | Pharmacologically active strong acid solutions | |
| Mann et al. | Pentazocine ulcers | |
| WO2015023226A1 (en) | Use of a composition comprising chitosan and a negatively charge polysaccharide for the treament of salivary dysfuntion | |
| WO2023177835A1 (en) | Treatment of uterine fibroids | |
| Al-Khuwaitir et al. | Chronic granulomatous disease with recurrent hepatic abscesses in an adult | |
| CA3033026A1 (en) | Composition for the treatment of pathologies of the urinary system | |
| MXPA97006182A (es) | Uso de acido hialuronico para el tratamiento de cistitis intersticial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120516 |